171 related articles for article (PubMed ID: 34872107)
21. Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma.
Blank O; von Tresckow B; Monsef I; Specht L; Engert A; Skoetz N
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD007110. PubMed ID: 28447341
[TBL] [Abstract][Full Text] [Related]
22. Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG.
Binkley MS; Rauf MS; Milgrom SA; Pinnix CC; Tsang R; Dickinson M; Ng AK; Roberts KB; Gao S; Balogh A; Ricardi U; Levis M; Casulo C; Stolten M; Specht L; Plastaras JP; Wright C; Kelsey CR; Brady JL; Mikhaeel NG; Hoppe BS; Terezakis SA; Picardi M; Della Pepa R; Kirova Y; Akhtar S; Maghfoor I; Koenig JL; Jackson C; Song E; Sehgal S; Advani RH; Natkunam Y; Constine LS; Eich HT; Wirth A; Hoppe RT
Blood; 2020 Jun; 135(26):2365-2374. PubMed ID: 32211877
[TBL] [Abstract][Full Text] [Related]
23. Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma.
Herbst C; Rehan FA; Skoetz N; Bohlius J; Brillant C; Schulz H; Monsef I; Specht L; Engert A
Cochrane Database Syst Rev; 2011 Feb; (2):CD007110. PubMed ID: 21328291
[TBL] [Abstract][Full Text] [Related]
24. Involved-node radiotherapy and modern radiation treatment techniques in patients with Hodgkin lymphoma.
Paumier A; Ghalibafian M; Beaudre A; Ferreira I; Pichenot C; Messai T; Lessard NA; Lefkopoulos D; Girinsky T
Int J Radiat Oncol Biol Phys; 2011 May; 80(1):199-205. PubMed ID: 21481723
[TBL] [Abstract][Full Text] [Related]
25. Decision analysis on alternative treatment strategies for favorable-prognosis, early-stage Hodgkin's disease.
Ng AK; Weeks JC; Mauch PM; Kuntz KM
J Clin Oncol; 1999 Nov; 17(11):3577-85. PubMed ID: 10550157
[TBL] [Abstract][Full Text] [Related]
26. Involved-Field Radiation Therapy Prevents Recurrences in the Early Stages of Hodgkin Lymphoma in PET-Negative Patients After ABVD Chemotherapy: Relapse Analysis of GHSG Phase 3 HD16 Trial.
Baues C; Goergen H; Fuchs M; Rosenbrock J; Celik E; Eich H; Kobe C; Voltin CA; Engert A; Borchmann P; Marnitz S
Int J Radiat Oncol Biol Phys; 2021 Nov; 111(4):900-906. PubMed ID: 34389407
[TBL] [Abstract][Full Text] [Related]
27. Vinblastine, bleomycin, and methotrexate chemotherapy plus irradiation for patients with early-stage, favorable Hodgkin lymphoma: the experience of the Gruppo Italiano Studio Linfomi.
Gobbi PG; Broglia C; Merli F; Dell'Olio M; Stelitano C; Iannitto E; Federico M; Bertè R; Luisi D; Molica S; Cavalli C; Dezza L; Ascari E
Cancer; 2003 Dec; 98(11):2393-401. PubMed ID: 14635074
[TBL] [Abstract][Full Text] [Related]
28. Improved survival in patients with limited stage IIIA Hodgkin's disease treated with combined radiation therapy and chemotherapy.
Marcus KC; Kalish LA; Coleman CN; Shulman LN; Rosenthal DS; Canellos GP; Mauch PM
J Clin Oncol; 1994 Dec; 12(12):2567-72. PubMed ID: 7989930
[TBL] [Abstract][Full Text] [Related]
29. Risk-adapted therapy for clinical stage I-II Hodgkin's disease: 7-years results of radiotherapy alone for low-risk disease, and ABVD and radiotherapy for high-risk disease.
MacKenzie RG; Franssen E; Wong R; Sawka C; Berinstein N; Cowan DH; Senn J; Poldre P
Clin Oncol (R Coll Radiol); 2000; 12(5):278-88. PubMed ID: 11315710
[TBL] [Abstract][Full Text] [Related]
30. An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma.
Hay AE; Klimm B; Chen BE; Goergen H; Shepherd LE; Fuchs M; Gospodarowicz MK; Borchmann P; Connors JM; Markova J; Crump M; Lohri A; Winter JN; Dörken B; Pearcey RG; Diehl V; Horning SJ; Eich HT; Engert A; Meyer RM;
Ann Oncol; 2013 Dec; 24(12):3065-9. PubMed ID: 24121121
[TBL] [Abstract][Full Text] [Related]
31. Consolidative radiation therapy for stage III Hodgkin lymphoma in patients who achieve complete response after ABVD chemotherapy.
Phan J; Mazloom A; Abboud M; Salehpour M; Reed V; Zreik T; Shihadeh F; Fisher C; Wogan C; Dabaja B
Am J Clin Oncol; 2011 Oct; 34(5):499-505. PubMed ID: 21537149
[TBL] [Abstract][Full Text] [Related]
32. A real-world study of combined modality therapy for early-stage Hodgkin lymphoma: too little treatment impacts outcome.
Chohan KL; Young JR; Lester S; Alhaj Moustafa M; Rosenthal A; Tun HW; Hoppe BS; Johnston PB; Micallef IN; Habermann TM; Ansell SM
Blood Adv; 2022 Jul; 6(14):4241-4250. PubMed ID: 35617689
[TBL] [Abstract][Full Text] [Related]
33. Cost-Effectiveness of PET Directed Versus Combined Modality Therapy for Early-Stage Favorable Hodgkin's Lymphoma.
Smith CP; Adefres B; Chang EM; Huang TQ; Parikh N; Raldow A
Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):e992-e999. PubMed ID: 35963771
[TBL] [Abstract][Full Text] [Related]
34. Ten-year survival outcomes for patients with early stage classical Hodgkin lymphoma: An analysis from Kentucky Cancer Registry.
Myint ZW; Shrestha R; Siddiqui S; Slone S; Huang B; Ramlal R; Monohan GP; Hildebrandt GC; Saeed H
Hematol Oncol Stem Cell Ther; 2020 Mar; 13(1):17-22. PubMed ID: 31629724
[TBL] [Abstract][Full Text] [Related]
35. The optimal dose of radiation in Hodgkin's disease: an analysis of clinical and treatment factors affecting in-field disease control.
Mendenhall NP; Rodrigue LL; Moore-Higgs GJ; Marcus RB; Million RR
Int J Radiat Oncol Biol Phys; 1999 Jun; 44(3):551-61. PubMed ID: 10348284
[TBL] [Abstract][Full Text] [Related]
36. Optimized volumetric modulated arc therapy versus 3D-CRT for early stage mediastinal Hodgkin lymphoma without axillary involvement: a comparison of second cancers and heart disease risk.
Filippi AR; Ragona R; Piva C; Scafa D; Fiandra C; Fusella M; Giglioli FR; Lohr F; Ricardi U
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):161-8. PubMed ID: 25863763
[TBL] [Abstract][Full Text] [Related]
37. Long-Term Outcomes in 10-Year Survivors of Early-Stage Hodgkin Lymphoma.
Bates JE; Parikh RR; Mendenhall NP; Morris CG; Hoppe RT; Constine LS; Hoppe BS
Int J Radiat Oncol Biol Phys; 2020 Jul; 107(3):522-529. PubMed ID: 32173399
[TBL] [Abstract][Full Text] [Related]
38. Long-Term Course of Patients With Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the German Hodgkin Study Group.
Eichenauer DA; Plütschow A; Fuchs M; von Tresckow B; Böll B; Behringer K; Diehl V; Eich HT; Borchmann P; Engert A
J Clin Oncol; 2015 Sep; 33(26):2857-62. PubMed ID: 26240235
[TBL] [Abstract][Full Text] [Related]
39. The role of radiation therapy in Hodgkin disease: experience and controversy. The 54th annual Janeway Lecture: 1989.
Levitt SH; Lee CK; Aeppli D; Lindgren B; Peterson BA
Cancer; 1992 Aug; 70(3):693-703. PubMed ID: 1623486
[TBL] [Abstract][Full Text] [Related]
40. Relapse patterns in early-PET negative, limited-stage Hodgkin lymphoma (HL) after ABVD with or without radiotherapy-a joint analysis of EORTC/LYSA/FIL H10 and NCRI RAPID trials.
Fiaccadori V; Neven A; Fortpied C; Aurer I; Andre M; Federico M; Counsell N; Phillips EH; Clifton-Hadley L; Barrington SF; Illidge T; Radford J; Raemaekers JMM
Br J Haematol; 2023 Mar; 200(6):731-739. PubMed ID: 36541117
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
